Elanco Animal Health Incorporated

ELAN NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Elanco Animal Hospital Shareholders

Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.
Would you like to receive future case and securities updates from Johnson Fistel, LLP via email?(Required)
Would you like to receive information about Johnson Fistel, LLP's free portfolio monitoring service?(Required)
By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, LLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471

There is no cost or obligation to you.

What is Johnson Fistel investigating? On June 27, 2024, Elanco issued a press release providing updates on the anticipated U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro. According to the release, Zenrelia is now expected to receive FDA approval in the third quarter of 2024, with a potential commercial launch planned for the fourth quarter of the same year. Elanco had previously set a launch timeline for Zenrelia in the third quarter. Additionally, the press release indicated that Credelio Quattro is now anticipated to receive FDA approval in the fourth quarter of 2024, adjusting from the previously projected approval timeline in the third quarter.

Following this news, the company’s stock price fell 20%, to close at $14.28 per share on June 27, 2024.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com